MilliporeSigma will provide its Provantage end-to-end development and manufacturing services to Y-mAbs Therapeutics, Inc. , a biopharmaceutical company, in support of Y-mAbs' monoclonal antibody in late-stage clinical development.

Following transfer of Y-mAbs' lead cell line to MilliporeSigma, services will include scale-up and GMP manufacturing of an antibody currently in latestage clinical development. Y-mAB expect to take delivery of cGMP drug product for its planned clinical trials by first half of 2017.

Source: MilliporeSigma/Merck KGaA